A clinical study of the immunogenicity and protective potency of a live recombinant GamLPV vaccine for intranasal use for the prevention of whooping cough in adult volunteers
Authors:
- Alevtina A. LidzhievaALAlevtina A. Lidzhieva
- Alisa Yu. MedkovaAMAlisa Yu. Medkova
- Sergey V. KulikovSKSergey V. Kulikov
- Ludmila N. SinyashinaLSLudmila N. Sinyashina
- Rezida A. SioundioukovaRSRezida A. Sioundioukova
- Andrey P. MarkovAMAndrey P. Markov
- Aleksey B. VervedaAVAleksey B. Verveda
- Natalia E. AbaevaNANatalia E. Abaeva
- Irina N. ChernyshovaICIrina N. Chernyshova
- Marina V. GavrilovaMGMarina V. Gavrilova
- Kristina K. BushkovaKBKristina K. Bushkova
- Ilya N. DyakovIDIlya N. Dyakov
Open Access
- 14 December 2024
- journal article
- Published by Central Research Institute for Epidemiology in Journal of microbiology, epidemiology and immunobiology
- Vol. 101 (6) , 779-793
Abstract
Introduction. The increase in incidence rate of pertussis worldwide, short-term insufficient immunity induced by acellular pertussis vaccines (TDaP) and their failure to provide antibacterial protection and to prevent transmission of infection in human population dictate the development of new pertussis vaccines. A new live recombinant pertussis vaccine for intranasal use (GamLPV) has completed preclinical studies in experiments on nonhuman primates and 2 phases of clinical trials involving adult healthy volunteers, in which the safety, immunogenicity and protective activity of the GamLPV were proven. Method and scheme of vaccine administration have been worked out. Aim. Confirmation of the immunogenicity and protective antibacterial potency of GamLPV in a randomized multicenter clinical trial on adult volunteers. Materials and methods. In this multicenter, clinical, randomized, placebo-controlled, double-blind study 260 healthy adults aged 18–65 years were divided into 2 groups: G1 — 210 volunteers (GamLPV) and G2 — 50 volunteers (placebo). 0.25 ml GamLPV delivered to each nostril (5 × 109 CFU) 60 days apart. Levels of Bordetella pertussis-specific IgG, IgA antibodies in blood serum and levels of B. pertussis-specific secretory IgA antibodies in nasopharyngeal aspirates were measured by ELISA method and agglutination test. The dynamics of elimination of attenuated B. pertussis bacteria after the first and second intranasal administration of GamLPV to volunteers was estimated by using qPCR. Results. Significant seroconversion of B. pertussis-specific IgG and IgA antibodies and growth of B. pertussis-specific secretory IgA antibody levels in nasal aspirates of volunteers were demonstrated. The dynamics of changes in the levels of IgG and IgA antibodies indicates a booster effect after second vaccination. Attenuated B. pertussis bacteria persist in the nose/oropharynx of vaccinated volunteers. The period of elimination after second vaccination is more than 2 times shorter than the period after the first one. The number of persistent B. pertussis bacteria after the second vaccination is less than 3% of the values after the first vaccination. Conclusion. High immunogenicity and the formation of antibacterial protection after single and double intranasal vaccination of GamLPV have been proven.Keywords
This publication has 15 references indexed in Scilit:
- Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus–diphtheria–acellular pertussis vaccine: a randomised, double-blind, phase 2b trialThe Lancet, 2023
- Pertussis (Whooping Cough)The Journal of Infectious Diseases, 2021
- Bordetella pertussis in School-Age Children, Adolescents, and Adults: A Systematic Review of Epidemiology, Burden, and Mortality in the Middle EastInfectious Diseases and Therapy, 2021
- Highlights of the 12th InternationalBordetellaSymposiumClinical Infectious Diseases, 2020
- Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation studyThe Lancet Infectious Diseases, 2020
- CLINICAL-DIAGNOSTIC VALUE OF BORDETELLA PERTUSSIS GENETIC MARKERS IN CONTACT PERSONS IN FAMILIAL FOCIJournal Infectology, 2019
- Will we have new pertussis vaccines?Vaccine, 2018
- Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate modelProceedings of the National Academy of Sciences, 2013
- Accumulation of avirulent Bordetella pertussis Bvg mutants in the course of experimental whooping cough in miceMolecular Genetics, Microbiology and Virology, 2013
- Development of live attenuated Bordetella pertussis strains expressing the universal influenza vaccine candidate M2eVaccine, 2011